Compare Biogen Inc (BIIB) vs Invesco Preferred ETF (PGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Invesco Preferred ETF — how do they compare? Biogen Inc trades at $204.1 (market cap $30.13B), while Invesco Preferred ETF trades at $10.65. The key difference: Biogen Inc is trading nearer its 52-week high, Invesco Preferred ETF nearer its low. Which is the better fit depends on your goals.
| BIIB | PGX | |
|---|---|---|
Market Cap | $30.13B | — |
Sector | Health | — |
52-Week High | $216.63 | $11.87 |
52-Week Low | $128.93 | $10.65 |
Enterprise Value | $37.20B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Biogen (BIIB) trades at $208.85, up 0.83% with bullish technical signals and strong institutional support. The company has delivered three consecutive earnings beats, with Q2 2026 EPS of $3.60 exceeding estimates by 22%. Recent acquisition of RayThera and raised 2026 guidance demonstrate strategic growth initiatives. Valuation metrics show a P/E of 36.21 and P/S of 3.01, while maintaining solid profitability with 73.99% gross margins.
Biogen presents a compelling investment case with strong earnings momentum and strategic acquisitions driving growth. However, investors face risks from declining legacy MS drug sales and net income margin compression from 16.86% in 2024 to 8.32% projected for 2026. The stock offers 12% upside to consensus price target of $234.47, supported by 62.5% analyst buy ratings.
PGX trades at $10.67, up 0.19% today, with a technical outlook leaning bearish based on moving averages. The stock shows neutral momentum oscillators. Recent corporate actions include declared dividends for 2026. Key financial ratios such as P/E and ROE are not available in the provided data, limiting fundamental assessment.
The outlook is cautious due to the bearish technical signals and lack of current fundamental data. Investment opportunity hinges on future financial disclosures and business performance. Risks include market volatility and potential operational challenges, requiring close monitoring of upcoming earnings reports and analyst updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Invesco Preferred ETF
The fund generally will invest at least 80% of its total assets in the components of the index. Strictly in accordance with its guidelines and mandated procedures, ICE Data Indices, LLC selects securities for the index, which is a market capitalization-weighted index designed to measure the performance of the fixed rate US dollar-denominated preferred securities market.
Read more on PGX →
